Yet you pull up your shirt and the midsection looks exactly the same as it did before you started testosterone replacement therapy
It is important to emphasize that these findings are derived exclusively from experimental and animal research, and comprehensive clinical studies are required to evaluate safety, effectiveness, and potential relevance in human cardiovascular conditions
| 2024 Edition In light of the exciting potential of BPC-157, it is an excellent addition to clinical research on effective ED treatments
References Rat anabolic/nitrogen retention dosing including des(13) IGF1 ~1.08 mg/kg/day Nephrectomized rat model des(13) IGF1 0.9 mg/kg/day for 7 days Des(13) IGF1 additional rat dosing example 1.2 mg/kg/day Invitro concentration range example 6.753 nM Biodistribution/clearance considerations for labeled des(13) IGF1 Research Resources Follistatin 344 (FS344) Human dosage only (what's actually in clinical studies) Quickstart Highlights Compound (Human clinical form): rAAV1.CMV.huFS344 (AAV1mediated follistatin FS344 gene transfer) Route used in trials: Intramuscular (IM) injections into targeted muscles How dosing is expressed: vector genomes per kilogram (vg/kg) (not mg) Human trial doses reported: 6 10 vg/kg and 1.2 10 vg/kg (BMD cohorts)
Conversely, consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events
it just takes a different route
